Psilocybin desynchronizes the human brain

Overview of study interpretation

• Discussion centers on psilocybin reducing functional connectivity (FC), especially in the default mode network (DMN), which is associated with inward-focused mentation.
• Some describe this as “desynchronizing” brain regions that usually activate together; others note FC is an abstract, coarse measure with issues such as how to treat negative correlations.
• Commenters stress fMRI’s low temporal resolution and focus on cortex; subcortical and thalamo‑cortical dynamics are likely important but under-resolved.
• There is interest in whether similar desynchronization occurs with LSD and other psychedelics; the paper itself suggests it generalizes at least to LSD.

Cognition, personality, and long-term effects

• Anecdotes: frequent users are described by some as more introspective, less neurotic, and less ego-focused; others strongly disagree or report no such pattern.
• Key open questions: whether reduced FC in DMN implies trade-offs in executive function, intelligence, or job performance; commenters note this remains unclear.
• Some report lasting positive changes (better emotional self‑observation), others report lasting negatives (brain fog, headaches, depersonalization, increased anxiety); mechanisms are unclear.

Subjective experiences and “mystical truths”

• Many describe powerful feelings of awe, insight, and “big sweeping Truths,” but several warn these are feelings, not guaranteed knowledge.
• Psychedelics are said to increase suggestibility and the risk of conspiracy thinking or intense religiosity in some people.
• Comparisons are made to dream states, meditation, and computer/effects‑pedal analogies for brain signaling; some caution against overextending tech metaphors.

Risks, mental health, and safety

• Multiple first-hand stories describe suicides or severe psychological crises following bad trips, often in people later recognized as having latent or familial psychotic vulnerabilities.
• A detailed subthread highlights that psychedelics can precipitate psychotic breaks in predisposed individuals (e.g., schizophrenia risk), especially before midlife.
• Strong advice: people with personal or family history of serious mental illness should be extremely cautious and consult clinicians; even then, risk assessment is imperfect.
• Access to firearms is repeatedly cited as turning transient crises into irreversible deaths; others push back or shift to broader gun‑risk debates.
• Seizure risk is mentioned anecdotally; robust data are noted as lacking.

Set, setting, and therapeutic use

• “Set and setting” are emphasized: mindset, environment, and trusted, sober guides are considered critical for safety and benefit.
• Traditional ceremonial contexts and modern clinical protocols (psilocybin + structured psychotherapy, prep and integration sessions) are contrasted with casual or clandestine use.
• Some advocate supervised trip centers or therapy‑only legalization; others stress personal freedom but agree on the need for better data and education.

Methodological and technical notes

• Sample size in the paper (e.g., n≈7 in key analyses) is criticized as very small; calls are made for n≈1000‑scale studies.
• Dose used (25 mg psilocybin) is described as medium, below typical “heroic” doses; delivery route may alter effective intensity.
• MRI‑during‑trip paradigms are seen as ecologically odd and uncomfortable, potentially biasing results, but still valuable for early mechanistic insight.